BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 11906760)

  • 1. The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant.
    Choi AH; McNeal MM; Flint JA; Basu M; Lycke NY; Clements JD; Bean JA; Davis HL; McCluskie MJ; VanCott JL; Ward RL
    Vaccine; 2002 Mar; 20(13-14):1733-40. PubMed ID: 11906760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrarectal immunization of mice with VP6 and either LT(R192G) or CTA1-DD as adjuvant protects against fecal rotavirus shedding after EDIM challenge.
    McNeal MM; Basu M; Bean JA; Clements JD; Lycke NY; Ramne A; Löwenadler B; Choi AH; Ward RL
    Vaccine; 2007 Aug; 25(33):6224-31. PubMed ID: 17629371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-independent protection against rotavirus infection of mice stimulated by intranasal immunization with chimeric VP4 or VP6 protein.
    Choi AH; Basu M; McNeal MM; Clements JD; Ward RL
    J Virol; 1999 Sep; 73(9):7574-81. PubMed ID: 10438847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4 T cells are the only lymphocytes needed to protect mice against rotavirus shedding after intranasal immunization with a chimeric VP6 protein and the adjuvant LT(R192G).
    McNeal MM; VanCott JL; Choi AH; Basu M; Flint JA; Stone SC; Clements JD; Ward RL
    J Virol; 2002 Jan; 76(2):560-8. PubMed ID: 11752147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection against rotavirus shedding after intranasal immunization of mice with a chimeric VP6 protein does not require intestinal IgA.
    McNeal MM; Stone SC; Basu M; Bean JA; Clements JD; Hendrickson BA; Choi AH; Ward RL
    Virology; 2006 Mar; 346(2):338-47. PubMed ID: 16375942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal or oral immunization of inbred and outbred mice with murine or human rotavirus VP6 proteins protects against viral shedding after challenge with murine rotaviruses.
    Choi AH; McNeal MM; Basu M; Flint JA; Stone SC; Clements JD; Bean JA; Poe SA; VanCott JL; Ward RL
    Vaccine; 2002 Sep; 20(27-28):3310-21. PubMed ID: 12213401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of gamma interferon and interleukin-17 production in intestinal CD4+ T cells with protection against rotavirus shedding in mice intranasally immunized with VP6 and the adjuvant LT(R192G).
    Smiley KL; McNeal MM; Basu M; Choi AH; Clements JD; Ward RL
    J Virol; 2007 Apr; 81(8):3740-8. PubMed ID: 17251301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of immune responses and partial protection in mice after skin immunization with rotavirus VP6 protein and the adjuvant LT(R192G).
    Choi AH; Smiley K; Basu M
    Vaccine; 2005 Mar; 23(17-18):2290-3. PubMed ID: 15755613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mice develop effective but delayed protective immune responses when immunized as neonates either intranasally with nonliving VP6/LT(R192G) or orally with live rhesus rotavirus vaccine candidates.
    VanCott JL; Prada AE; McNeal MM; Stone SC; Basu M; Huffer B; Smiley KL; Shao M; Bean JA; Clements JD; Choi AH; Ward RL
    J Virol; 2006 May; 80(10):4949-61. PubMed ID: 16641286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rotavirus 2/6 viruslike particles administered intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT), and LT-R192G induce protection from rotavirus challenge.
    O'Neal CM; Clements JD; Estes MK; Conner ME
    J Virol; 1998 Apr; 72(4):3390-3. PubMed ID: 9525668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-dependent and -independent protection following intranasal immunization of mice with rotavirus particles.
    McNeal MM; Rae MN; Bean JA; Ward RL
    J Virol; 1999 Sep; 73(9):7565-73. PubMed ID: 10438846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a Bacillus subtilis-based rotavirus vaccine.
    Lee S; Belitsky BR; Brinker JP; Kerstein KO; Brown DW; Clements JD; Keusch GT; Tzipori S; Sonenshein AL; Herrmann JE
    Clin Vaccine Immunol; 2010 Nov; 17(11):1647-55. PubMed ID: 20810679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective efficacy of rotavirus 2/6-virus-like particles combined with CT-E29H, a detoxified cholera toxin adjuvant.
    Siadat-Pajouh M; Cai L
    Viral Immunol; 2001; 14(1):31-47. PubMed ID: 11270595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal administration of an Escherichia coli-expressed codon-optimized rotavirus VP6 protein induces protection in mice.
    Choi AH; Basu M; McNeal MM; Bean JA; Clements JD; Ward RL
    Protein Expr Purif; 2004 Dec; 38(2):205-16. PubMed ID: 15555936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective immunity and antibody-secreting cell responses elicited by combined oral attenuated Wa human rotavirus and intranasal Wa 2/6-VLPs with mutant Escherichia coli heat-labile toxin in gnotobiotic pigs.
    Yuan L; Iosef C; Azevedo MS; Kim Y; Qian Y; Geyer A; Nguyen TV; Chang KO; Saif LJ
    J Virol; 2001 Oct; 75(19):9229-38. PubMed ID: 11533185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants.
    McCluskie MJ; Weeratna RD; Clements JD; Davis HL
    Vaccine; 2001 Jun; 19(27):3759-68. PubMed ID: 11395211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IFN-gamma is the only anti-rotavirus cytokine found after in vitro stimulation of memory CD4+ T cells from mice immunized with a chimeric VP6 protein.
    McNeal MM; Stone SC; Basu M; Clements JD; Choi AH; Ward RL
    Viral Immunol; 2007 Dec; 20(4):571-84. PubMed ID: 18158731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Particle bombardment-mediated DNA vaccination with rotavirus VP6 induces high levels of serum rotavirus IgG but fails to protect mice against challenge.
    Choi AH; Knowlton DR; McNeal MM; Ward RL
    Virology; 1997 May; 232(1):129-38. PubMed ID: 9185596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rotavirus 2/6 virus-like particles administered intranasally in mice, with or without the mucosal adjuvants cholera toxin and Escherichia coli heat-labile toxin, induce a Th1/Th2-like immune response.
    Fromantin C; Jamot B; Cohen J; Piroth L; Pothier P; Kohli E
    J Virol; 2001 Nov; 75(22):11010-6. PubMed ID: 11602741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection of mice against rotavirus challenge following intradermal DNA immunization by Biojector needle-free injection.
    Choi AH; Smiley K; Basu M; McNeal MM; Shao M; Bean JA; Clements JD; Stout RR; Ward RL
    Vaccine; 2007 Apr; 25(16):3215-8. PubMed ID: 17280754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.